GlassScriptPhysician profile
Keith B Elbourne
NPI 1194742122
$1,664.09
in general payments reported to CMS, 2019-2025
26 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2021: $252 · 2022: $536 · 2023: $273 · 2024: $220 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712 · Education: $35.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.75 |
| Education | $35.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $287.65 | 2023-2025 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $152.31 | 2021-2024 | Ova1 |
| Amgen INC. | $114.27 | 2021-2024 | Evenity, Prolia |
| Organon LLC | $112.26 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $111.98 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $78.15 | 2021-2022 | |
| Abbvie INC. | $77.26 | 2022-2023 | |
| Smith+Nephew, INC. | $58.31 | 2019-2024 | Pico 14 |
| Hologic Sales and Service, LLC | $57.94 | 2022-2023 | Aptima |
| Daiichi Sankyo INC. | $57.36 | 2021-2022 | |
| Exeltis, USA INC. | $57.36 | 2023-2025 | Slynd |
| Coopersurgical, INC. | $57.05 | 2022-2025 | Paragard T 380a |
| Amag Pharmaceuticals, INC. | $51.81 | 2019 | |
| Sumitomo Pharma America, INC. | $51.22 | 2024-2025 | Myfembree |
| Avion Pharmaceuticals | $50.37 | 2021-2023 | Balcoltra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $45.84 | 2019-2022 | |
| Stryker Corporation | $45.68 | 2024 | 1788, Spy-Phi System |
| Myovant Sciences INC. | $33.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.84 | 2022-2025 | |
| Mycovia Pharmaceuticals, INC. | $27.02 | 2023 | Vivjoa |
| Merck Sharp & Dohme LLC | $24.90 | 2021 | |
| Davol INC. | $19.27 | 2022 | |
| Millicent US INC | $17.32 | 2023 | Femring, Intrarosa |
| Agile Therapeutics, INC. | $16.98 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $15.37 | 2021 | |
| Pfizer INC. | $13.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Elbourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.